Catalog No.
YME43201
Expression system
E. coli
Species
Mus musculus (Mouse)
Protein length
Thr31-Thr177
Predicted molecular weight
18.56 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P47741
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134
OX40-OX40L Axis in Cutaneous T-Cell Lymphomas: Pathogenic, Prognostic, and Potential Therapeutic Perspectives., PMID:40427608
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering., PMID:40404202
Recognition of different subsets of alloreactive T cells by activation-induced markers., PMID:40204006
Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P/YAP-mediated angiogenesis., PMID:40026246
Activation of immune checkpoint OX40 inhibits HBV replication in a mouse model., PMID:39923582
Specific immune response to M. tuberculosis and ability to in vitro control mycobacterial replication are not impaired in subjects with immune-mediated inflammatory disease and tuberculosis infection., PMID:39872515
Tumor-Infiltrating Immune Cells and HLA Expression as Potential Biomarkers Predicting Response to PD-1 Inhibitor Therapy in Stage IV Melanoma Patients., PMID:39766316
A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies., PMID:39745391
Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists., PMID:39636970
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity., PMID:39543823
Dysregulation of Regulatory T Cells and Autoimmune Sequelae in DRESS: Insights From Flow Cytometry and NanoString Analysis., PMID:39487714
Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells., PMID:39474429
A Novel Subset of Regulatory T Cells Induced by B Cells Alleviate the Severity of Immunological Diseases., PMID:39465485
Research progress in OX40/OX40L in allergic diseases., PMID:39404736
Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds., PMID:39115359
From structural design to delivery: mRNA therapeutics for cancer immunotherapy., PMID:38855617
Soluble levels of 4-1BB (CD137) and OX40 (CD134) are associated with cancer progression in gastric adenocarcinoma., PMID:38853545
The role of OX40 ligand/OX40 axis signalling in atopic dermatitis., PMID:38836560
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction., PMID:38737794
NOD/Scid IL2Rγnull Mice Reconstituted with PBMCs from Patients with Atopic Dermatitis or Psoriasis Vulgaris Reflect the Respective Phenotype., PMID:38736522
The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis., PMID:38700255
Multiparameter immunoprofiling for the diagnosis and differentiation of progressive versus nonprogressive nontuberculous mycobacterial lung disease-A pilot study., PMID:38640113
Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis., PMID:38625053
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis., PMID:38607026
High frequencies of alpha common cold coronavirus/SARS-CoV-2 cross-reactive functional CD4+ and CD8+ memory T cells are associated with protection from symptomatic and fatal SARS-CoV-2 infections in unvaccinated COVID-19 patients., PMID:38605956
OX40/OX40 ligand and its role in precision immune oncology., PMID:38526805
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target., PMID:38236520
Development of a cellular model to study CCR8 signaling in tumor-infiltrating regulatory T cells., PMID:38231448
Enhanced detection of antigen-specific T cells by a multiplexed AIM assay., PMID:38228152
Comparison of Follicular Helper T-Cell Markers with the Expression of the Follicular Homing Marker CXCR5 in Peripheral T-Cell Lymphomas-A Reappraisal of Follicular Helper T-Cell Lymphomas., PMID:38203606
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer., PMID:38140230
SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain., PMID:38012843
The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity., PMID:37932534
Diagnostic Value of CD25, CD69, and CD134 on Tuberculosis-Specific Antigen-Stimulated CD4+ T Cells for Tuberculous Pleurisy., PMID:37809012
Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis., PMID:37663117
Azithromycin downregulates ICOS (CD278) and OX40 (CD134) expression and mTOR activity of TCR-activated T cells to inhibit proliferation., PMID:37633240
Assessing SARS-CoV-2-specific T-cell reactivity in late convalescents and vaccinees: Comparison and combination of QuantiFERON and activation-induced marker assays, and relation with antibody status., PMID:37220145
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults., PMID:37199270
Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome., PMID:37051254
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)., PMID:36927527
An optimized flow cytometry protocol for simultaneous detection of T cell activation induced markers and intracellular cytokines: Application to SARS-CoV-2 immune individuals., PMID:36842524
DNA methylation of GITR, OX40, 4-1BB, CD27 , and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma., PMID:36735464
Multicentric IL-5-positive Castleman Disease With Nephrotic Syndrome Relapsed After Rituximab Treatment., PMID:36593046
Elevated expression of TNFRSF4 impacts immune cell infiltration and gene mutation in hepatocellular carcinoma., PMID:36591653
Biological Activity of Mouse OX40L-Igg Purified With Two Novel Resins., PMID:39006201
Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia., PMID:36151238
The absence of AhR in CD4+ T cells in patients with acute graft-versus-host disease may be related to insufficient CTCF expression., PMID:36056390
Optimal CD8+ T cell effector function requires costimulation-induced RNA-binding proteins that reprogram the transcript isoform landscape., PMID:35725727
In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity., PMID:35653749
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses., PMID:35607995
For research use only. Not for human or drug use.
